<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607149</url>
  </required_header>
  <id_info>
    <org_study_id>2016-002552-24</org_study_id>
    <nct_id>NCT03607149</nct_id>
  </id_info>
  <brief_title>Pemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation Strategies</brief_title>
  <acronym>PKAPIR</acronym>
  <official_title>Pemetrexed in Maintenance in Patients With Impaired Renal Function: Randomized Phase 4 Multicenter Study Comparing 2 Dose Calculation Strategies (PKAPIR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pemetrexed is used in the treatment of non-small cell lung cancer (NSCLC). Its elimination is
      mainly renal and its nephrotoxicity requires an interruption of treatment when the CrCLCG
      falls below 45 mL / min. Patients with NSCLC frequently have impaired renal function by other
      cytotoxic drugs.

      The dose adjustment of pemetrexed is performed as a function of body surface area (SC)
      without any pharmacokinetic rational. The challenge is to treat patients with renal
      insufficiency (RR) with a safe dose, based on CRCL, providing equivalent biological exposure
      to patients with preserved renal function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Primary objective: Evaluate the impact of calculating the dose of pemetrexed to be
           administered versus creatine clearance according to Cockcroft-Gault (CrCLCG) versus body
           surface area (SC) on median time before discontinuation of treatment for renal function
           ≤ 45mL / min in patients treated for non-small cell lung cancer predominantly
           non-squamous in maintenance.

        -  Secondary objective: To evaluate the impact of calculating the dose of pemetrexed to be
           administered versus CRCLCG versus SC over time to treatment discontinuation,
           progression-free survival (PFS), and patient overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2017</start_date>
  <completion_date type="Anticipated">January 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 6, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median time until treatment is stopped due to renal function ≤ 45mL / min</measure>
    <time_frame>1 year</time_frame>
    <description>From date of randomization until the date of treatment is stopped</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 100 weeks</time_frame>
    <description>From date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>STANDARD ARM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calculation of the dose of pemetrexed as a function of body surface area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXPERIMENTAL ARM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calculation of the pemetrexed dose as a function of the Clearance of creatine (CrCLCG)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>standard arm : calculating the dose of pemetrexed according to body surface area
experimental arm: calculation of the dose of pemetrexed as a function of creatinine clearance (CrCLCG)</description>
    <arm_group_label>EXPERIMENTAL ARM</arm_group_label>
    <arm_group_label>STANDARD ARM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years of age

          -  Patient with non-small cell lung cancer predominantly non-epidermoid histologically
             documented

          -  Patient who is scheduled to initiate treatment or undergoing maintenance therapy by
             pemetrexed

          -  Neutrophils&gt; 1500 / mm3; Chips&gt; 100,000 / mm3

          -  Informed, dated and signed consent For patients of childbearing age, effective
             contraceptive method

          -  Creatinine clearance according to the Cockcroft-Gault formula between 70 and 45 mL /
             min

          -  PS = 0 or 1

        Exclusion Criteria:

          -  Patient with a contraindication to pemetrexed therapy

          -  Patient with symptomatic brain metastases

          -  Pregnant or nursing women

          -  Patient under guardianship or curatorship or subject to a system of protection for
             persons of full age

          -  Patient not affiliated to a social security scheme (beneficiary or beneficiary)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bruno COUDERT</last_name>
    <phone>03 80 73 75 28</phone>
    <email>bcoudert@cgfl.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie REDERSTORFF</last_name>
    <phone>03.45.34.81.16</phone>
    <email>erederstorff@cgfl.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH William Morey</name>
      <address>
        <city>Chalon-sur-Saône</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Fleur QUILLOT</last_name>
      <email>Fleur-marie.quilot@ch-chalon71.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jerome POIROT</last_name>
      <email>jerome.poirot@ch-chalon71.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno COUDERT</last_name>
      <phone>03 80 73 75 28</phone>
      <email>bcoudert@cgfl.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emilie REDERSTORFF</last_name>
      <phone>03.45.34.81.16</phone>
      <email>erederstorff@cgfl.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Bruno COUDERT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélie LAGRANGE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure FAVIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Universitaire Hospitalier de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal FOUCHER</last_name>
      <phone>03 80 29 37 72</phone>
      <email>pascal.foucher@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pemetrexed</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Clearance of creatine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

